• Humacyte secured a contract for Symvess under the U.S. Department of Veterans Affairs’ Strategic Acquisition Center Surgical Implant - Next Generation program.
• The agreement makes the surgical implant available through the VA’s preferred procurement channel, expanding access across 170 VA hospitals.
• Symvess won FDA clearance in December 2024 for extremity vascular trauma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200800PRIMZONEFULLFEED9723504) on May 20, 2026, and is solely responsible for the information contained therein.